Please assess the completion status of the following clinical trial:

Trial Title: Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Males, 45 years or older, with benign prostatic hyperplasia, including lower urinary tract symptoms for at least 6 months prior to Visit 1 and an International Prostate Symptom Score (IPSS) greater than or equal to 13 at Visit 2.~* Agree not to use approved or experimental benign prostatic hyperplasia or erectile dysfunction treatments anytime during the study~* Have not taken finasteride or dutasteride therapy, any other lower urinary tract symptom (LUTS) therapy or phosphodiesterase type 5 (PDE5) inhibitors for specified duration of time prior to Visit 2.~* Have a prostate specific antigen (PSA) score within acceptable range defined for study or negative biopsy of the prostate for cancer within 12 months of Visit 1.~Exclusion Criteria:~* History of urinary retention or lower urinary tract (bladder) stones 6 months before the start of the study~* History of bladder outlet obstruction or urethral obstruction due to stricture, valves, sclerosis, or tumor.~* History of cardiac conditions including angina requiring certain treatment with nitrates, heart disease or coronary conditions including myocardial infarction, bypass surgery, angioplasty or stent placement for a specified time before starting the study.~* Certain neurological conditions associated with bladder problems or injuries to the brain or spinal cord within a specified time before starting the study.~* Nitrate use

- Gender: MALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): placebo tablet
- 2 (Type: ACTIVE_COMPARATOR): 2.5 mg tadalafil tablet
- 3 (Type: ACTIVE_COMPARATOR): 5 mg tadalafil tablet
- 4 (Type: ACTIVE_COMPARATOR): 10 mg tadalafil tablet
- 5 (Type: ACTIVE_COMPARATOR): 20 mg tadalafil tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).